Chengdu huasun technology group Inc. , LTD. (SZSE:000790) agreed to acquire Sichuan Bohaoda Biotechnology Co., Ltd. from Sichuan Yuanhong Biotechnology Co., Ltd. and Chengdu Bohaoda Biotechnology Co., Ltd. for CNY 1 billion on June 20, 2023. Chengdu huasun technology group will pay the consideration by issuing new shares at CNY 3.9 per share. Sichuan Bohaoda Biotechnology reported total assets of CNY 299.1127 million, net assets of CNY 196.1454 million, operating revenue of CNY 131.2527 million and net profit of CNY 46.7881 million till December 31, 2022.

The transaction is subject to approval from sellers, shareholders of Chengdu huasun technology group, approval from Shenzhen Stock Exchange and CSRC. The transaction has been approved by Directorate meeting of Chengdu huasun technology group. CSC Financial Co., Ltd. acted as financial advisor, Sichuan Huaxin(Group) Certified Public Accountants Co.,Ltd. acted as accountant and Grandway Law Offices acted as legal advisor to Chengdu huasun technology group Inc. , LTD.